Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14746836 | 0.94 | RORC (0.88) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14746393 | 0.93 | RORC (0.86) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14744539 | 0.92 | RORC (0.84) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14754265 | 0.92 | RORC (1.00) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14744228 | 0.91 | RORC (0.83) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14746481 | 0.91 | RORC (0.83) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14744232 | 0.91 | RORC (1.00) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14746802 | 0.90 | RORC (0.82) | RORCCYP2C9CYP2C19 | |
| SCHEMBL29448169 | 0.90 | RORC (1.00) | RORCCYP2C9CYP2C19 | |
| SCHEMBL14746799 | 0.90 | RORC (1.00) | RORCCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017268-A1 | METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-21 | — | — | US | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017268-A1 | METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION | RORB, IL17A, RORC | RORC 3/4885CYP2C9 4213/4885CYP2C19 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.